CIBUS INC (CBUS)
US17166A1016 - Common Stock
We assign a fundamental rating of 3 out of 10 to CBUS. CBUS was compared to 573 industry peers in the Biotechnology industry. Both the profitability and financial health of CBUS have multiple concerns. CBUS is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
CBUS had negative earnings in the past year.
CBUS had a negative operating cash flow in the past year.
CBUS had negative earnings in each of the past 5 years.
CBUS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CBUS has a Return On Assets (-52.74%) which is in line with its industry peers.
CBUS's Return On Equity of -107.90% is in line compared to the rest of the industry. CBUS outperforms 43.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.74% | ||
| ROE | -107.9% | ||
| ROIC | N/A |
ROA(3y)-67.69%
ROA(5y)-63.77%
ROE(3y)-177.62%
ROE(5y)-143.55%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CBUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CBUS has more shares outstanding
CBUS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CBUS has an improved debt to assets ratio.
2.2 Solvency
CBUS has an Altman-Z score of -1.63. This is a bad value and indicates that CBUS is not financially healthy and even has some risk of bankruptcy.
CBUS's Altman-Z score of -1.63 is in line compared to the rest of the industry. CBUS outperforms 53.70% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CBUS is not too dependend on debt financing.
CBUS has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: CBUS outperforms 49.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.63 |
ROIC/WACCN/A
WACC10.31%
2.3 Liquidity
CBUS has a Current Ratio of 1.14. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.
CBUS has a Current ratio of 1.14. This is amonst the worse of the industry: CBUS underperforms 85.92% of its industry peers.
A Quick Ratio of 1.14 indicates that CBUS should not have too much problems paying its short term obligations.
CBUS's Quick ratio of 1.14 is on the low side compared to the rest of the industry. CBUS is outperformed by 84.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.67% over the past year.
The Revenue has grown by 826.88% in the past year. This is a very strong growth!
The Revenue has been growing by 49.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)8.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.62%
Revenue 1Y (TTM)826.88%
Revenue growth 3Y-57.61%
Revenue growth 5Y49.91%
Sales Q2Q%319%
3.2 Future
The Earnings Per Share is expected to grow by 15.23% on average over the next years. This is quite good.
CBUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 182.70% yearly.
EPS Next Y84.18%
EPS Next 2Y36.93%
EPS Next 3Y23.92%
EPS Next 5Y15.23%
Revenue Next Year116.73%
Revenue Next 2Y170.03%
Revenue Next 3Y191.71%
Revenue Next 5Y182.7%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CBUS. In the last year negative earnings were reported.
Also next year CBUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CBUS's earnings are expected to grow with 23.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y23.92%
5. Dividend
5.1 Amount
CBUS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CIBUS INC
NASDAQ:CBUS (9/19/2024, 6:46:08 PM)
After market: 3.88 0 (0%)3.88
+0.28 (+7.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap101.66M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.74% | ||
| ROE | -107.9% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)8.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y84.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)826.88%
Revenue growth 3Y-57.61%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y